News

Sandoz & Anr v Bristol-Myers Squibb & Ors [2022] EWHC 1831 (Pat)15 July 2022Andrew Lykiardopoulos QC appeared for Sandoz and Justin Turner QC appeared for Teva  in proceedings to invalidate 4 patents owned by Bristol-Myers Squibb (“BMS”) and Pfizer, both of whom counterclaimed that the generic products which Sandoz and Teva intended to launch on the UK market would infringe. The patents related to a formulation of apixaban […]
Congratulations to Joshua Marshall1 July 2022Chambers is delighted to announce that Joshua Marshall has accepted an offer of tenancy at 8 New Square and will begin practice as a member of chambers in October 2022. Joshua joins chambers after a successful career as an IP solicitor where he was ranked as a “Rising Star” by Legal 500 and Managing IP.
Neurim Pharmaceuticals (1991) Ltd & Anr v Teva UK Ltd [2022] EWHC 1641 (Pat)29 June 2022Charlotte May QC and Henry Ward successfully appeared for the defendant (“Teva”) in a second application brought by the claimants (“Neurim”) for interim injunctive relief, the first application (also successfully defended by Charlotte May QC) having been rejected by Mellor J on 14 April 2022.  The underlying claim related to infringement of Neurim’s patent for […]
Alcon Research v Pharmathen [2022] EWCA Civ 84528 June 2022Lindsay Lane KC and William Duncan appeared for the second defendant (“Aspire”) in an appeal of the judgment of Meade J finding that a patent for the use of fluprostenol isopropyl ester (“FIE”), a prostaglandin F2α (“PGF2α”) analogue, also known as travoprost, for the treatment of glaucoma and ocular hypertension was valid and infringed.  The […]
Justin Turner QC joins 8 New Square20 June 2022Justin Turner QC, a leading advocate and IP specialist with a particular interest in pharmaceutical and biotech cases, will be joining 8 New Square on 20th June 2022. Members of chambers have worked with Justin for many years and are delighted to welcome him following his decision to move from his previous chambers. Justin has appeared in many of the leading cases at all […]
Managing IP Awards 202215 June 20228 New Square’s Jaani Riordan won the UK Junior IP Barrister of the Year award at this year’s Managing IP Awards, with Isabel Jamal also being nominated in this category. Daniel Alexander QC, Adrian Speck QC, Andrew Lykiardopoulos QC, Charlotte May QC, James Abrahams QC and Lindsay Lane QC were all nominated in the Senior […]
Shazam v Only Fools The Dining Experience [2022] EWHC 1379 (IPEC)8 June 2022Shazam, the company holding the rights in the sitcom Only Fools and Horses previously owned by its creator, John Sullivan, sued Only Fools The Dining Experience (‘OFDE’) and related companies and individuals for using characters, catchphrases, themes and other material taken from the sitcom in their immersive theatrical dining experience “Only Fools The (cushty) Dining […]
Advanced Bionics AG & Anr v Med-El Elektromedizinische Geräte Gmbh [2022] EWHC 1345 (Pat)1 June 2022Andrew Lykiardopoulos QC appeared as lead counsel for the claimants (“Advanced Bionics”) in proceedings brought against the defendant (“Med-El”) to revoke a patent relating to MRI-safe disk magnets and/or a declaration that Advanced Bionics’ implant device did not infringe.  Med-El counterclaimed for infringement, with the proceedings conducted through the Shorter Trials Scheme. The trial in […]
Saint-Gobain Adfors SAS v 3M Innovative Properties Co [2022] EWHC 1018 (Pat)9 May 2022James Abrahams QC and Michael Conway successfully appeared for the claimant (“Saint-Gobain”) in a claim to revoke a European patent (“the Patent”) registered by the defendant (“3M”) for dish-shaped abrasive particles with a recessed surface. The Patent claimed that dish-shaped abrasive particles, with a sloping sidewall and a specific thickness ratio, increase the grinding performance […]
Neurim Pharmaceuticals (1991) Ltd & Anr v Teva UK Ltd [2022] EWHC 954 (Pat)26 April 2022Charlotte May QC successfully appeared as lead counsel for the defendant (“Teva”) in opposing an application for an interim injunction brought by the claimants (“Neurim”) for an order restraining Teva from disposing of, offering for sale, selling or supplying a generic version of Circadin. The hearing of the application had been expedited by Roth J. […]